See more : Andina Acquisition Corp. III (ANDA) Income Statement Analysis – Financial Results
Complete financial analysis of SOHM, Inc. (SHMN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SOHM, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Smart Parking Limited (SPZ.AX) Income Statement Analysis – Financial Results
- Sadr Logistics Company (1832.SR) Income Statement Analysis – Financial Results
- Signify Health, Inc. (SGFY) Income Statement Analysis – Financial Results
- Robertet SA (RBTEF) Income Statement Analysis – Financial Results
- Accel Entertainment, Inc. (TPGH-UN) Income Statement Analysis – Financial Results
SOHM, Inc. (SHMN)
About SOHM, Inc.
SOHM, Inc. develops, manufactures, markets, and distributes generic and private label pharmaceutical products in the United States. It offers analgesics, antibiotics, anti-cold, and anti-inflammatory drugs, as well as over-the-counter, cosmeceuticals, and nutraceutical products. The company also exports its products. SOHM, Inc. was founded in 2005 and is based in Corona, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 402.65K | 347.09K | 324.91K | 235.08K | 162.90K | 422.99K | 173.96K | 124.26K | 278.14K |
| Cost of Revenue | 145.48K | 161.71K | 151.29K | 144.68K | 38.49K | 218.95K | 70.59K | 30.26K | 450.19K |
| Gross Profit | 257.16K | 185.37K | 173.61K | 90.40K | 124.41K | 204.04K | 103.37K | 94.01K | -172.05K |
| Gross Profit Ratio | 63.87% | 53.41% | 53.43% | 38.45% | 76.37% | 48.24% | 59.42% | 75.65% | -61.86% |
| Research & Development | 22.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 530.11K | 91.34K | 84.29K | 56.55K | 80.10K | 151.62K | 167.24K | 114.16K | 230.29K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 552.16K | 91.34K | 84.29K | 56.55K | 80.10K | 151.62K | 167.24K | 114.16K | 230.29K |
| Cost & Expenses | 697.65K | 253.05K | 235.59K | 201.23K | 118.58K | 370.57K | 237.83K | 144.42K | 680.48K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.90K | 1.46K | 1.04K | 755.00 | 1.18K | 273.00 | 270.00 | 1.66K | 234.81K |
| Depreciation & Amortization | 167.90K | 228.49K | 236.56K | 206.30K | 171.86K | 4.40K | 52.52K | 22.82K | 141.86K |
| EBITDA | -295.00K | 94.04K | 89.32K | 33.85K | 44.31K | 56.82K | -63.87K | -20.16K | -260.48K |
| EBITDA Ratio | -73.27% | 27.09% | 27.49% | 14.40% | 27.20% | 13.43% | -36.72% | -16.22% | -93.65% |
| Operating Income | -295.00K | 94.04K | 89.32K | 33.85K | 44.31K | 52.42K | -63.87K | -20.16K | -402.34K |
| Operating Income Ratio | -73.27% | 27.09% | 27.49% | 14.40% | 27.20% | 12.39% | -36.72% | -16.22% | -144.65% |
| Total Other Income/Expenses | -1.90K | -1.46K | -1.04K | -756.00 | -1.18K | -273.00 | -270.00 | -1.66K | -234.81K |
| Income Before Tax | -296.90K | 92.58K | 88.28K | 33.09K | 43.13K | 52.15K | -64.14K | -21.82K | -637.15K |
| Income Before Tax Ratio | -73.74% | 26.67% | 27.17% | 14.08% | 26.48% | 12.33% | -36.87% | -17.56% | -229.07% |
| Income Tax Expense | -167.90K | -228.49K | -236.56K | -206.30K | -171.86K | -156.74K | -52.52K | -22.82K | -5.00 |
| Net Income | -296.90K | 92.58K | 88.28K | 33.09K | 43.13K | 52.15K | -64.14K | -21.82K | -637.15K |
| Net Income Ratio | -73.74% | 26.67% | 27.17% | 14.08% | 26.48% | 12.33% | -36.87% | -17.56% | -229.07% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 1.60B | 1.58B | 1.58B | 1.58B | 1.56B | 1.55B | 1.44B | 1.44B | 1.55B |
| Weighted Avg Shares Out (Dil) | 1.60B | 1.58B | 1.58B | 1.58B | 1.56B | 1.55B | 1.44B | 1.44B | 1.55B |
SOHM Files Provisional Patent on ABBIE's ‘Smart Gene-Editing' That Uses Latest Enzymes and Guide RNA to Resolve Off-Target Gene-Editing Limitations
CHINO HILLS, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN) (the “Company”), a pharmaceutical, nutraceutical, cosmeceutical and biotech Company that manufactures and markets generic drugs covering numerous treatment categories, announces today the Company...
SOHM Announces Business Outlook for 2024
CHINO HILLS, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN) (the “Company”), a pharmaceutical, nutraceutical and cosmeceutical Company that manufactures and markets generic drugs covering numerous treatment categories, announced:
SOHM Announces New CDMO GMP Manufacturing Facility in Carlsbad, California
CHINO HILLS, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announced today its new manufacturing facility at...
SOHM OTC Self-care Launches Suite of 13 New SOHM Nutrients' Brand Chewables
CHINO HILLS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announced:
SOHM Collaborates with University of Arizona Center for Innovation to Advance ABBIE, a Groundbreaking Non-Viral Gene-Editing Technology
CHINO HILLS, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announces:
SOHM Announces Its Acquisition of ABBIE, a World-Class Gene-Editing Platform Which Can Deliver Genetic Payloads Using Non-Viral Vectors
CHINO HILLS, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announces today that it has acquired:
SOHM, Inc. Expands Its Advisory Board, Appointing Dr. Krishna Bhat, M.D, Ph.D., FACC, as Chief Medical Advisor
CHINO HILLS, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announces today the appointment of Dr. Krishna Bhat,...
SOHM, Inc. Announce the Appointment of Dr. David Aguilar, Ph.D. as a Chief Operating Officer with the Company with Immediate Effect
CHINO HILLS, CA / ACCESSWIRE / August 8, 2023 / SOHM, Inc. (OTC PINK:SHMN), a generic pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, is pleased to announce today the appointment of Dr....
SOHM Inc. Signs LOI to Acquire Stem Cell Disruptive Technology and Patents
CHINO HILLS, CA/ ACCESSWIRE/ / August 1, 2023 / SOHM, Inc. (OTC PINK:SHMN), a generic pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announces today that the company has signed a letter of...
SOHM Inc. Announces the Closure of Finances-Funding for its Various Projects
SOHM Inc. Secures Funding for Its Diverse Projects. CHINO HILLS, CA / ACCESSWIRE / July 25, 2023 / SOHM, Inc. (OTC PINK:SHMN), a company that manufactures and markets generic drugs, nutraceuticals, and cosmeceuticals for various treatment categories, announces today that...
Source: https://incomestatements.info
Category: Stock Reports